Lead
A U.S. Food and Drug Administration (FDA) advisory committee has unanimously recommended approving Moderna's new flu vaccine, mFlusiva, according to multiple reports. The vaccine, built on the same mRNA technology used in COVID-19 shots, is intended for adults aged 50 and older and could become the world's first mRNA-based flu vaccine if the FDA grants final approval.
The recommendation follows a review of safety and efficacy data from a late-stage trial involving approximately 40,000 participants aged 50 and above. The committee's vote, reported by the Jerusalem Post, covers two age groups: people 50 to 64 and those 65 and older. For the older group, the committee requested that Moderna conduct an additional post-market study, as noted in Jerusalem Post's coverage.
Coverage Comparison
Coverage of the FDA advisory committee's decision comes from two outlets with distinct focuses. The Guardian, reporting from a UK perspective, framed the development as part of a broader debate among US health advisers over the first mRNA-based flu vaccine. Its report emphasized the vaccine's potential to improve flu protection and its faster manufacturing process compared to traditional vaccines. The Jerusalem Post, with a MENA-focused audience, highlighted the unanimous vote and the vaccine's effectiveness, presenting the news in a technical and formal manner without any loaded language.
Both sources agree on the core facts: the vaccine uses mRNA technology, is intended for people 50 and older, and showed about 27% greater efficacy in preventing influenza compared to a standard flu shot. They also both note that the FDA published a favorable review of the data, reporting no safety concerns. However, only The Guardian mentions a public dispute earlier this year between Moderna and a former top FDA official over the vaccine's application.
Key Claims
- Effectiveness: Moderna's mFlusiva vaccine reduced flu cases by about 27% compared to a routinely used standard flu vaccine in a late-stage trial, according to both The Guardian and Jerusalem Post.
- Target Population: The vaccine is intended for adults aged 50 and older, as reported by both sources.
- Advisory Vote: The FDA's vaccine advisory committee voted unanimously in favor of the vaccine, as reported by Jerusalem Post. This detail was not mentioned in The Guardian's coverage.
- Safety Data: The FDA published a favorable review of the vaccine's data and reported no safety concerns, according to The Guardian.
- Additional Study: For adults aged 65 and older, the committee requested an additional study after the vaccine enters the market, as reported by Jerusalem Post.
- Regulatory Dispute: Earlier this year, a top FDA official at the time blocked Moderna's application, leading to a public dispute. This was reported solely by The Guardian.
Perspectives
Public Health Benefit: Proponents, as reflected in Jerusalem Post's coverage, see the mRNA flu vaccine as a significant advancement. The 27% improved efficacy could translate into fewer flu cases and hospitalizations, particularly among older adults who are most vulnerable to severe complications. The faster manufacturing capability of mRNA technology also offers a strategic advantage in responding to flu virus mutations.
Regulatory Caution: The FDA committee's request for additional study in adults 65 and older, as noted by Jerusalem Post, reflects a cautious approach to ensuring the vaccine's effectiveness in the most at-risk population. The Guardian's mention of the earlier dispute over the vaccine's comparison to a high-dose alternative suggests ongoing scientific debate about the appropriate standard for evaluating new flu vaccines.
Scientific Debate: The Guardian's report highlights a prior disagreement between Moderna and a former FDA vaccine chief, who argued that the company should have compared its shot to a high-dose flu vaccine recommended for seniors, rather than a standard-dose brand. This underscores the evolving standards in vaccine evaluation and the complexities of approving novel technologies.